TSTickerStar
Company alerts/STRO
STRO company alerts

STRO updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for STRO. Subscribe to STRO alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent STRO alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

EarningsOfficial company source

STRO Q3 2026 STRO-006 Phase 1 Initiation First patient dosed in October 2026, Beat Guidance by +2023.0

STRO beat prior Q3 2026 STRO-006 Phase 1 Initiation guidance by +2023.0. Sutro Biopharma reported Q3 2026 revenue of $9.1 million, down 6% year-over-year from $9.7 million in Q3 2025, with the decrease driven by lower collaboration revenue. Net loss improved to $31.5 million or -$1.90 per share compared to a net loss of $56.9 million or -$6.66 per share in the prior-year period. The company initiated STRO-006 Phase 1 with first patient dosed in October 2026, meeting its Q3 2026 guidance milestone, and expects it...

Read source-backed brief
SEC filingSEC filing

STRO 10-Q filed 2026-11-12 | Key takeaways

STRO filed its 10-Q; the most relevant disclosure change is reduced Restructuring and Related Costs: Restructuring costs declined to $16K in Q3 2026 from $9.6M in Q3 2025, reflecting completion of the March and September 2025 Restructuring Plans that reduced workforce by approximately two-thirds and deprioritized the luvelta (STRO-002) program. Customer concentration: Astellas Pharma Inc. represented 99.5% of revenue; Astellas Pharma Inc. represented 99.2% of revenue.

Read source-backed brief